EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	716	febrifugine or halofuginone or isofebrifugine	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/07/19 13:30
L2	1111	"protozoan infection"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/07/19 13:31
L3	6	L1 and L2	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/07/19 13:31

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXK

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS
                 Web Page for STN Seminar Schedule - N. America
                 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS
        MAR 15
NEWS
     3 MAR 16
                 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30
                RDISCLOSURE reloaded with enhancements
NEWS 7
        APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/Caplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30
                INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01
                 New CAS web site launched
NEWS 13
        MAY 08
                 CA/CAplus Indian patent publication number format defined
NEWS 14
       MAY 14
                 RDISCLOSURE on STN Easy enhanced with new search and display
                 fields
NEWS 15
        MAY 21
                 BIOSIS reloaded and enhanced with archival data
NEWS 16
        MAY 21
                 TOXCENTER enhanced with BIOSIS reload
NEWS 17
        MAY 21
                 CA/CAplus enhanced with additional kind codes for German-
                 patents
NEWS 18
        MAY 22
                 CA/CAplus enhanced with IPC reclassification in Japanese
                 patents
NEWS 19
         JUN 27
                 CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20
        JUN 29
                 STN Viewer now available
NEWS 21
         JUN 29
                 STN Express, Version 8.2, now available
NEWS 22
         JUL 02
                 LEMBASE coverage updated
NEWS 23
        JUL 02
                 LMEDLINE coverage updated
NEWS 24
        JUL 02
                 SCISEARCH enhanced with complete author names
NEWS 25
         JUL 02
                 CHEMCATS accession numbers revised
NEWS 26
        JUL 02
                 CA/CAplus enhanced with utility model patents from China
NEWS 27
         JUL 16
                 CAplus enhanced with French and German abstracts
NEWS 28
        JUL 18
                CA/CAplus patent coverage enhanced
NEWS EXPRESS
             29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
              CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS LOGIN
             Welcome Banner and News Items
NEWS IPC8
             For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * STN. Columbus

FILE 'HOME' ENTERED AT 13:33:52 ON 19 JUL 2007

=> file caplus medline biosis embase

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

0.21 0.21

FILE 'CAPLUS' ENTERED AT 13:34:30 ON 19 JUL 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:34:30 ON 19 JUL 2007

FILE 'BIOSIS' ENTERED AT 13:34:30 ON 19 JUL 2007 Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:34:30 ON 19 JUL 2007 Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> s febrifugine

229 FEBRIFUGINE

=> s halofuginone

1096 HALOFUGINONE

=> s protozoan infection

5560 PROTOZOAN INFECTION

=> dup rem L1

PROCESSING COMPLETED FOR L1

139 DUP REM L1 (90 DUPLICATES REMOVED)

=> s L4 and (AY<2003 or PY<2003 or PRY<2003)

'2003' NOT A VALID FIELD CODE

'2003' NOT A VALID FIELD CODE

2 FILES SEARCHED...

'2003' NOT A VALID FIELD CODE

101 L4 AND (AY<2003 OR PY<2003 OR PRY<2003)

=> s L5 and L3

0 L5 AND L3

=> s L5 and infections

4 L5 AND INFECTIONS

=> d 1-4 ibib abs

ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2000:21603 CAPLUS

DOCUMENT NUMBER:

132:73628

TITLE:

Febrifugine derivatives having antimalarial

activity

INVENTOR(S): PATENT ASSIGNEE(S): Oshima, Yoshiteru; Takaya, Yoshiaki; Wataya, Yusuke

Taiho Pharmaceutical Co., Ltd., Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

GI

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ----------JP 2000007673 Α 20000111 JP 1998-172578 19980619 <--JP 3740284 B2 20060201 PRIORITY APPLN. INFO.: JP 1998-172578 19980619 <--OTHER SOURCE(S): MARPAT 132:73628

AB Febrifugine or isofebrifugine derivs. I (R1, R2 = H, hydrocarbon; either R3 or R4 is H and the other is OH or OAc; CR3R4 may form C:O; R5 = acyl, selectively releasable ether-type protective group) or their salts are useful for prevention and treatment of malarial infections. Febrifugine extracted from Dichroa febrifuga was stirred in Me2CO in the presence of silica gel to give acetonylfebrifugine, which inhibited Plasmodium falciparum with EC50 of 3.2 + 10-10 M.

ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

Ι

ACCESSION NUMBER: 1950:31220 CAPLUS

DOCUMENT NUMBER:

44:31220

ORIGINAL REFERENCE NO.: 44:6086d-h

TITLE:

Obtaining febrifugine alkaloids

INVENTOR(S):

Koepfli, Joseph B.; Mead, James F.; Brockman, John A.,

PATENT ASSIGNEE(S):

United States of America, as represented by the Secy.

of the Army

DOCUMENT TYPE:

Patent

LANGUAGE:

Unavailable

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ____ ----------US 2504847 19500418 US 1948-26428 19480511 <--Ground roots of Dichroa febrifuga are extracted repeatedly with 0.1 N HCl for AB 48 hrs. and are soaked until test with Dragendorff's reagent is neg. The alkaloids are adsorbed on fuller's earth (amount calculated from a graph) with excess HCl and long stirring, and filtered. The filter cake is made into a thin paste with H2O, Na2CO3 is added to pH 8.5 or higher, BuOH (3 times amount of H2O) is added, and the mixture is shaken for 1-3 hrs. The extraction with BuOH is repeated, 0.5 volume ligroin (b. $60-70^{\circ}$) and 0.5 volume % 6 N HCl are added to the BuOH, the aqueous layer is separated, the BuOH is extracted

with 0.1 N HCl, the combined aqueous exts. are neutralized with Na2CO3, extracted

with 20 volume % BuOH in CHCl3, this is extracted with 0.25 N HCl, and the neutralization-extraction cycle is repeated. The final BuOH-CHCl3 is evaporated,

and the residue is collected by use of Et2O, crystallized from EtOH and excess 12 N HCl, and recrystd. by dissolving in 50% EtOH and adding absolute EtOH to 90% to give febrifugine-2HCl: free base (I) m. 152-4° (from CHCl3) and 139-40° (from EtOH). Filtrates from I-2HCl are evaporated, and H2O and Na2CO3 are added and extracted with CHCl3 to give isofebrifugine (II), recrystd. rapidly from hot MeOH. II heated at m. p. or refluxed in EtOH is partially converted to I; similarly some II is obtained from I in hot CHCl3. The roots contain 0.05-0.10% alkaloid and far more I than II. For more phys. data see abstract from J. Am. Chemical Society in C.A. 41, 5984a. I has LD50 of 2.5-3.0 mg./kg. in the white mouse and has delayed toxic manifestations. In rhesus monkeys I is more than 300 times as toxic (subacute) than quinine, causes loss of weight at doses of 0.6 mg./kg. daily, and is 50 times as active as quinine against Plasmodium cynomolgi infections.

L7 ANSWER 3 OF 4 MEDLINE ON STN ACCESSION NUMBER: 75157215 MEDLINE DOCUMENT NUMBER: PubMed ID: 1128923

TITLE: Laboratory studies with some recent anticoccidials.

AUTHOR: , Ryley J F; Wilson R G

SOURCE: Parasitology, (1975 Apr) Vol. 70, No. 2, pp.

203-22.

Journal code: 0401121. ISSN: 0031-1820.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 197508

ENTRY DATE: Entered STN: 10 Mar 1990

Last Updated on STN: 10 Mar 1990 Entered Medline: 8 Aug 1975

AB The activities of monensin, lasalocid and halofuginone against Eimeria tenella, E. brunetti and E. necatrix have been studied under laboratory conditions. Complete control of experimental infections in the chick, separable from toxicity, was not obtained with monensin, but was achieved with the other two compounds at levels of 150 and 6 ppm in the food respectively. All three compounds appear to inhibit coccidial development very early in the life-cycle, and to have a fairly rapid lethal effect, monensin and lasalocid more so than the febrifugine derivative. In vivo observations have been supplemented with in vitro studies. Some discussion of the difficulties of relating laboratory experiments to field performance is given.

L7 ANSWER 4 OF 4 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 89169326 EMBASE

DOCUMENT NUMBER: 1989169326

TITLE: New leads to the treatment of protozoal infections

based on natural product molecules.

AUTHOR: Phillipson J.D.; O'Neill M.J.

CORPORATE SOURCE: Department of Pharmacognosy, The School of Pharmacy,

University of London, London WC1N 1AX, United Kingdom Acta Pharmaceutica Nordica, (1989) Vol. 1, No. 3, pp.

131-144.

ISSN: 1100-1801 CODEN: APNOEE

COUNTRY: Sweden DOCUMENT TYPE: Journal

SOURCE:

FILE SEGMENT: 037 Drug Literature Index

LANGUAGE: English

ENTRY DATE: Entered STN: 12 Dec 1991

Last Updated on STN: 12 Dec 1991

=> s L2 and infections 85 L2 AND INFECTIONS => dup rem L8 PROCESSING COMPLETED FOR L8 48 DUP REM L8 (37 DUPLICATES REMOVED) => s L9 and (AY<2003 or PY<2003 or PRY<2003) '2003' NOT A VALID FIELD CODE '2003' NOT A VALID FIELD CODE 2 FILES SEARCHED... '2003' NOT A VALID FIELD CODE L10 41 L9 AND (AY<2003 OR PY<2003 OR PRY<2003) => s protozoal or protozoan 323012 PROTOZOAL OR PROTOZOAN => s L10 and L11 11 L10 AND L11 => d 1-11 L12 ibib abs L12 ANSWER 1 OF 11 MEDLINE on STN ACCESSION NUMBER: 90320070 MEDLINE DOCUMENT NUMBER: PubMed ID: 2115212 Elimination of Theileria buffeli infections from TITLE: cattle by concurrent treatment with primaquine phosphate and halofuginone lactate. AUTHOR: Stewart N P; de Vos A J; Shiels I CORPORATE SOURCE: Queensland Department of Primary Industries, Animal Research Institute, Wacol, Queensland, Australia. SOURCE: Tropical animal health and production, (1990 May) Vol. 22, No. 2, pp. 109-15. Journal code: 1277355. ISSN: 0049-4747. PUB. COUNTRY: SCOTLAND: United Kingdom Journal; Article; (JOURNAL ARTICLE) DOCUMENT TYPE: LANGUAGE: English Priority Journals FILE SEGMENT: ENTRY MONTH: 199008 ENTRY DATE: Entered STN: 21 Sep 1990 Last Updated on STN: 21 Sep 1990 Entered Medline: 21 Aug 1990 Fifty splenectomised calves naturally infected with Theileria buffeli were AB treated with primaquine phosphate (ICI, UK) and halofuginone lactate (Hoechst, Australia) either separately or in combination. Infections in treated calves were monitored for up to 26 weeks by examining Giemsa stained peripheral blood films for piroplasms and by an immunofluorescent antibody test. When used alone neither of the drugs eliminated infection. The most successful results were obtained when two treatments of halofuginone lactate, at a rate of 1 mg kg-1 body weight and six treatments of primaquine phosphate, at a rate of 2 mg kg-1 body weight, were administered concurrently. No theilerial relapses were observed in 14 of 16 calves so treated, and no antibody to T. buffeli was detected in these calves beyond the twelfth week after treatment. The

results have application in the preparation of Theileria-free calves for

use in the production of living vaccines against babesiosis and

anaplasmosis.

L12 ANSWER 2 OF 11 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 1986:277331 BIOSIS

DOCUMENT NUMBER: PREV198682021194; BA82:21194

TITLE: ASSESSMENT OF ANTICOCCIDIALS AGAINST INTESTINAL EIMERIA IN

GALLUS-GALLUS-F-DOMESTICA.

AUTHOR(S): GOMEZ E [Reprint author]; BLANDINO T

CORPORATE SOURCE: DEP PARASITOL-MICOL, CENT NAC SANIDAD AGROPECUARIA, SAN

JOSE DE LAS LAJAS, LA HABANA

SOURCE: Revista de Salud Animal, (1985) Vol. 7, No. 3,

pp. 275-280.

CODEN: RSANDH. ISSN: 0253-570X.

DOCUMENT TYPE: Article

FILE SEGMENT:

LANGUAGE:

SPANISH

Entered STN: 4 Jul 1986

ENTRY DATE:

Last Updated on STN: 4 Jul 1986

The activity of amprolium (125 and 240 ppm), halofuginone (3 ppm), monensin (100 ppm), salinomicin (60 ppm) and sulphdimidine (2000

ppm) against experimental mixed infections of fowl intestinal

coccidiae was assessd. Criteria for effectiveness comprised weight gain, number of discharged oocysts and alterations in feces. Amprolium (240

ppm), halofuginone and sulphadimidine showed moderate

anticoccidial effect according to the described conditions.

L12 ANSWER 3 OF 11 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 1985:164831 BIOSIS

DOCUMENT NUMBER:

PREV198529054827; BR29:54827

TITLE:

IMPLICATIONS OF CHEMOTHERAPY OF THEILERIA-LAWRENCEI

INFECTIONS CORRIDOR DISEASE IN CATTLE.

AUTHOR(S):

POTGIETER F T [Reprint author]; ROOS J A; DE VOS A J VET RES INST, PO BOX ONDERSTEPOORT 0110

CORPORATE SOURCE:

SOURCE:

South African Journal of Science, (1985) Vol. 81,

No. 1, pp. 44.

Meeting Info.: ANNUAL MEETING OF THE PARASITOLOGICAL SOCIETY OF SOUTHERN AFRICA, JOHANNESBURG, SOUTH AFRICA,

JUNE 28-29, 1984. S AFR J SCI. CODEN: SAJSAR. ISSN: 0038-2353.

DOCUMENT TYPE:

Conference; (Meeting)

FILE SEGMENT:

BR ENGLISH LANGUAGE:

L12 ANSWER 4 OF 11 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER:

1981:138321 BIOSIS

DOCUMENT NUMBER:

PREV198171008313; BA71:8313

TITLE:

THE ANTI COCCIDIAL EFFICACY OF ARPRINOCID IN BROILER

CHICKENS UNDER FLOOR PEN CONDITIONS.

AUTHOR(S):

SCHROEDER J [Reprint author]; SMITH C J Z; HARVEY R G MSD RES CENT, PRIV BAG 3, 1685 HALFWAY HOUSE, S AFR

CORPORATE SOURCE: SOURCE:

Journal of the South African Veterinary Association, (

1980) Vol. 51, No. 1, pp. 59-61. CODEN: JAVTAP. ISSN: 0038-2809.

DOCUMENT TYPE:

Article

FILE SEGMENT: BA LANGUAGE: **ENGLISH**

The efficacy of arprinocid was tested against artificial infections of mixtures of Eimeria spp. in broiler chickens under floor pen conditions in 3 experiments. Treatment with arprinocid at 60 ppm over 56 days significantly increased the live mass gain and feed efficiency of broiler chickens. This increase compared favorably with that obtained by treatment with lasalocid, robenidine and halofuginone. Birds treated with arprinocid had substantially reduced numbers of sporulated oocysts in their litter, and less severe lesion scores than non-mediated birds.

L12 ANSWER 5 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights

reserved on STN

ACCESSION NUMBER: 2002078501 EMBASE

TITLE: Parasites of goats: A guide to diagnosis and control.

AUTHOR: Taylor M.

SOURCE: In Practice, (2002) Vol. 24, No. 2, pp. 76-89. .

ISSN: 0263-841X CODEN: IPRCDH

COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
030 Pharmacology

037 Drug Literature Index

LANGUAGE: English SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 14 Mar 2002

ectoparasitic infections of goats.

Last Updated on STN: 14 Mar 2002

AB Goats share a number of diseases in common with sheep and cattle and this is particularly true with regard to parasitic infections. The most important endoparasitic diseases seen in goats are parasitic gastroenteritis caused by gastrointestinal nematodes, and coccidiosis caused by protozoan parasites of the genus Eimeria. Other internal parasitic infections seen in goats include cryptosporidiosis, a rapidly emerging zoonotic infection of domestic animals (and humans), adult tapeworms and several metacestodes, and insect larvae of the family Oestridae (bots and warbles). Ectoparasites may be found either permanently on goats (eg, mites and lice) or only when they come to feed (eg, ticks and flies). Such parasites may be a source of annoyance or may result in illthrift and disease. This article discusses the pathogenesis, diagnosis and control of the major endo- and

L12 ANSWER 6 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER:

2001368223 EMBASE

TITLE:

Chemotherapeutic approaches to protozoa: Coccidiae -

Current level of knowledge and outlook.

AUTHOR:

Greif G.; Harder A.; Haberkorn A.

CORPORATE SOURCE:

G. Greif, Animal Health Business Group, Research and Development, Biological and Chemical Evaluation, 51368

Leverkusen, Germany. gisela.greif.ah@bayer.ag.de

SOURCE:

Parasitology Research, (2001) Vol. 87, No. 11, pp. 973-975.

Refs: 4

ISSN: 0932-0113 CODEN: PARREZ

COUNTRY:

Germany

DOCUMENT TYPE: FILE SEGMENT:

Journal; Article
004 Microbiology
030 Pharmacology

O30 Pharmacology
O37 Drug Literature Index

LANGUAGÉ: English

SUMMARY LANGUAGE:

English

ENTRY DATE:

Entered STN: 2 Nov 2001

Last Updated on STN: 2 Nov 2001

AB Progress in the treatment and prophylaxis of cystforming coccidial infections (Neospora, Sarcocystis, Toxoplasma) and Cryptosporidium infections has been limited (Table 1; Haberkorn 1996; Croft 1997; Wang 1997). However, new possibilities have been opened up in the treatment of Eimeria-induced coccidiosis in poultry and mammals, due to improvements in treatment and/or metaphylaxis. A new polyether antibiotic, semduramycin, has recently been added to the range of effective prophylactic preparations. The development of resistance to anticoccidial agents is now posing similar problems to those encountered with malaria, coccidiosis in poultry being particularly affected. Because no new active ingredient from a new family of chemical substances has been

developed for more than 10 years, the following approaches are being adopted to get round this problem: the use of older preparations which have not been used for a long time, the introduction of combinations such as narasin/nicarbazin or methyl benzoquate/clopidol and the alternating use of anticoccidial agents in rotation and shuttle programmes. The goal of a real alternative, i.e. vaccination, has been achieved to a certain extent in the form of live vaccines for laying hens and broiler breeders and is being practiced in some countries.

L12 ANSWER 7 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights

reserved on STN

ACCESSION NUMBER: 1998333813 EMBASE

TITLE:

[Cryptosporidium infections in immunocompetent

and immnocompromised host].

L'INFEZIONE DA CRIPTOSPORIDIO NELL'OSPITE IMMUNOCOMPETENTE

E NEL PAZIENTE IMMUNOCOMPROMESSO.

CORPORATE SOURCE:

Maisto A.; Sorrentino A.R.; Gaeta G.B.

A. Maisto, Istituto di Malattie Infettive, Seconda

Universita, Napoli, Italy

SOURCE:

Infezioni in Medicina, (1998) Vol. 6, No. 3, pp. 139-147. .

Refs: 111

ISSN: 1124-9390 CODEN: INMEFK

COUNTRY:

Italy

DOCUMENT TYPE: Journal; Article FILE SEGMENT: 004 Microbiology

006 Internal Medicine

017 Public Health, Social Medicine and Epidemiology

026 Immunology, Serology and Transplantation

037 Drug Literature Index

LANGUAGE: Italian

SUMMARY LANGUAGE: English; Italian

ENTRY DATE:

Entered STN: 28 Oct 1998

Last Updated on STN: 28 Oct 1998

Prior to 1980 infections with Cryptosporidium species were AB

considered extremely rare in humans. During the eighties, evidence

cumulates that this intracellular protozoan was often

responsible of self-limiting diarrheal illness in immunocompetent patients and of a prolonged, life-threatening disease in immunocompromised hosts, especially patients with AIDS. The aim of this paper is to review the present knowledge on Cryptosporidium biology, epidemiology, pathogenesis, diagnosis, therapy and highlight recent studies on the clinical aspects of this infection.

L12 ANSWER 8 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights

reserved on STN

ACCESSION NUMBER: 93113989 EMBASE

DOCUMENT NUMBER:

1993113989

TITLE:

Opportunistic infections: Treatment and

developmental therapeutics of cryptosporidiosis and

isosporiasis.

AUTHOR:

St. Georgiev V.

CORPORATE SOURCE:

Nat. Inst. Allergy/Infectious Dis., National Institutes of

Health, Solar Building, Bethesda, MD 20892, United States Drug Development Research, (1993) Vol. 28, No. 4, pp.

445-459.

ISSN: 0272-4391 CODEN: DDREDK

COUNTRY:

SOURCE:

United States

Journal; General Review 004

FILE SEGMENT:

DOCUMENT TYPE:

Microbiology 030 Pharmacology

Drug Literature Index 037

LANGUAGE:

SUMMARY LANGUAGE:

English English

ENTRY DATE:

Entered STN: 30 May 1993

Last Updated on STN: 30 May 1993

Cryptosporidium sp. and Isospora sp. are coccidian protozoans AB taxonomically related to Toxoplasma gondii and Plasmodium sp. Although associated with many animal species, these pathogens are also the causative agents of cryptosporidiosis and isosporiasis, 2 invasive opportunistic infections in humans. In immunocompetent hosts, the infections are usually self-limited, flu-like gastrointestinal disorders which resolve spontaneously. In immunocompromised patients, however, cryptosporidiosis is a severe, debilitating, and prolonged illness, with high morbidity and no known therapy effective against it. Spiramycin has been proven largely ineffective. In recent years, however, the use of immunotherapy is being actively pursued as one potentially useful approach for the treatment of cryptosporidiosis. Azithromycin, a new macrolide antibiotic, has also shown promise in preclinical studies. In the case of isosporiasis, the combination of trimethoprim and sulphamethoxazole has been found to be effective, although AIDS patients have shown a high rate of relapse and, therefore, the need for suppressive maintenance therapy.

L12 ANSWER 9 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights

reserved on STN

ACCESSION NUMBER: 92069393 EMBASE

DOCUMENT NUMBER:

1992069393

TITLE:

Protozoal gastrointestinal infections.

AUTHOR:

Hamer D.H.; Keusch G.T.

CORPORATE SOURCE:

New England Medical Center Hospitals-Tufts University School of Medicine, Department of Medicine, Division of Geographic Medicine and Infectious Diseases, 750 Washington

Street, NEMCH 341 Boston, MA 02111, United States

SOURCE:

Current Opinion in Infectious Diseases, (1992) Vol. 5, No.

1, pp. 88-98. .

ISSN: 0951-7375 CODEN: COIDE5

COUNTRY:

United Kingdom

DOCUMENT TYPE:

Journal; General Review

FILE SEGMENT:

004 Microbiology 037 Drug Literature Index

048 Gastroenterology

LANGUAGE:

English

SUMMARY LANGUAGE:

English

ENTRY DATE:

Entered STN: 29 Mar 1992

Last Updated on STN: 29 Mar 1992

DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L12 ANSWER 10 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER:

92019139 EMBASE

DOCUMENT NUMBER:

1992019139

TITLE:

Therapy for enteric protozoa.

AUTHOR:

Janoff E.N.

CORPORATE SOURCE:

VA Medical Center, Infectious Disease Section (111F), One

Veterans Drive, Minneapolis, MN 55417, United States

SOURCE:

Current Opinion in Infectious Diseases, (1991) Vol. 4, No.

6, pp. 820-825. .

ISSN: 0951-7375 CODEN: COIDE5

COUNTRY:

United Kingdom

DOCUMENT TYPE:

Journal; General Review

FILE SEGMENT:

004 Microbiology

006 Internal Medicine 037 Drug Literature Index

048 Gastroenterology

LANGUAGE: SUMMARY LANGUAGE: English English

ENTRY DATE:

Entered STN: 20 Mar 1992

Last Updated on STN: 20 Mar 1992

AB Enteric protozoa are common, identifiable, and often treatable causes of enteric disease in children and adults worldwide. In the last decade, use of newer diagnostic methods and the rapid growth of the population of immunocompromised patients has led to an expanded list of potential protozoan pathogens. Prominent among these pathogens are Cryptosporidium and Microsporidium organisms, both of which are associated with chronic diarrheal disease in patients with human immunodeficiency virus infection and for which effective therapy is not yet available. The challenge for the next decade is to establish reliable and accessible diagnostic techniques for identifying new enteric protozoan infections and to establish safe and effective therapeutic regimens.

L12 ANSWER 11 OF 11 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights

reserved on STN

ACCESSION NUMBER: 81201226 EMBASE

DOCUMENT NUMBER: 1981201226

TITLE: The chemotherapy of protozoal infections

of veterinary importance.

AUTHOR: Joyner L.P.

CORPORATE SOURCE: Parasitol. Dept., Cent. Veter. Lab., Min. Agric. Fisheries

Food, Weybridge, United Kingdom

SOURCE: Journal of Protozoology, (1981) Vol. 28, No. 1, pp. 17-19.

CODEN: JPROAR

COUNTRY: United States DOCUMENT TYPE: Journal

FILE SEGMENT: 037 Drug Literature Index

LANGUAGE: English

ENTRY DATE: Entered STN: 9 Dec 1991

Last Updated on STN: 9 Dec 1991

DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER '